Terbinafine clinical studies

Revision as of 21:05, 7 January 2014 by Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Terbinafine}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERBINAFINE (TERBINAFINE HYDROCHLORIDE) TABLET [...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Terbinafine
LamISIL®,FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]


[1]

References

  1. ↑ "TERBINAFINE (TERBINAFINE HYDROCHLORIDE) TABLET [AUROBINDO PHARMA LIMITED]".

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Terbinafine_clinical_studies&oldid=927722"